Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

2047 results about "Non specific" patented technology

In medical parlance, "non-specific" (often spelled "nonspecific" in the medical world) means not due to any single known cause, and alternatively, not directed at a particular agent but having a general effect.

Controlling the serving, with a primary document, of ads from a first source, subject to a first compensation scheme, and ads from a second source, subject to a second compensation scheme

An advertising entity manages determinations, bidding, and / or billing for serving “generic advertisements” on a primary document. Generic ads are not for specific merchants or products; rather they lead users to a secondary document containing more specific information, product listings, and / or merchant listings. Such information and / or listings are determined to be relevant to a generic concept corresponding to the generic ad. For example, when a user selects a generic ad, they may be presented with a secondary document including product listings. If the user selects a merchant's product listing, then that merchant compensates an ad serving entity and / or a publisher of the primary document. Such management might include choosing or generating an appropriate generic advertisement creative for a potential advertising situation. A determination of whether or not to render a generic ad instead of one or more typical advertiser-managed ads may use an expected value of rendering the generic ad versus showing the advertiser-managed ad(s). The result of this determination may be reflected in a bid associated with the generic ad. Generic ads will often be useful for primary documents (e.g., Web pages) that are non-specific.
Owner:GOOGLE LLC

Two step lateral flow assay methods and devices

Lateral flow assay devices and methods for detecting a first member of a specific binding pair in a sample which comprises a plurality of nonspecific binding pair members are adapted for two step determinations. In one embodiment, a two step lateral flow assay method for identifying IgE antibodies in a sample comprises applying a sample to a sample port of a device, wherein the device is adapted to deliver the sample to a lateral flow matrix having a plurality of IgE antigen species immobilized at respective positions at a first location The two step method further comprises allowing the sample to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a second location downstream of the first location, applying liquid buffer to the lateral flow matrix to mobilize labeled reagent which is adapted to bind anti-IgE antibody and is dried on the lateral flow matrix at a location upstream of the delivery of the filtered sample to the lateral flow matrix, and allowing labeled reagent mobilized by the liquid buffer to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a location downstream of the first location. Further embodiments comprise additional lateral flow immunoassay devices and methods for identifying IgE antibodies in a sample.
Owner:PHADIA AB

Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the Fv to lower the isoelectric point

The invention provides recombinant immunotoxins that have been modified from a parental immunotoxin to lower liver toxicity. The immunotoxins are created by specifically mutating charged residues in the framework regions of the heavy chain, the light chain, or both, of the antibody portion or antigen-binding fragment thereof of the parental immunotoxin to reduce the pI of the antibody or fragment. In preferred forms, the antibody portion of the parental is an anti-Tac, anti-mesothelin, or anti-LewisY antigen antibody or antigen-binding fragment, and in particularly preferred forms the antibody portion is an M16 dsFv, a St6 dsFv or a Mt9 dsFv, or a sequence that has at least 90% sequence identity to one of these molecules but retain the particular mutations that lower pI without affecting antibody activity. The invention further provides nucleic acids encoding the recombinant immunotoxins of the invention, expression cassettes comprising the nucleic acids, and host cells comprising the expression cassettes. The invention also provides a method for killing a cell comprising an antigen on the surface of the cell, the method comprising contacting the cell with a recombinant immunotoxin of the invention that has an antibody or antigen-binding fragment thereof that binds specifically to the antigen on the surface of the cell, and uses of immunotoxins of the invention for the manufacture of medicaments.
Owner:HEALTH & HUMAN RESOURCES GOVERNMENT OF THE UNITED STATES THE AS REPRESENTED BY THE SEC OF THE DEPT OF
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products